Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,401
archived clinical trials in
Alzheimer Disease

MAyflOwer RoAD Study: A Study of RO4602522 in Patients With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy
A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study To Investigate The Efficacy And Safety Of RO4602522 Added To Background Alzheimer's Disease Therapy In Patients With Moderate Severity Alzheimer's Disease
Status: Enrolling
Updated:  11/17/2016
Clinical Research Facility
mi
from
Oklahoma City, OK
MAyflOwer RoAD Study: A Study of RO4602522 in Patients With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy
A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study To Investigate The Efficacy And Safety Of RO4602522 Added To Background Alzheimer's Disease Therapy In Patients With Moderate Severity Alzheimer's Disease
Status: Enrolling
Updated: 11/17/2016
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
MAyflOwer RoAD Study: A Study of RO4602522 in Patients With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy
A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study To Investigate The Efficacy And Safety Of RO4602522 Added To Background Alzheimer's Disease Therapy In Patients With Moderate Severity Alzheimer's Disease
Status: Enrolling
Updated:  11/17/2016
Clinical Research Facility
mi
from
Oklahoma City, OK
MAyflOwer RoAD Study: A Study of RO4602522 in Patients With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy
A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study To Investigate The Efficacy And Safety Of RO4602522 Added To Background Alzheimer's Disease Therapy In Patients With Moderate Severity Alzheimer's Disease
Status: Enrolling
Updated: 11/17/2016
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
MAyflOwer RoAD Study: A Study of RO4602522 in Patients With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy
A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study To Investigate The Efficacy And Safety Of RO4602522 Added To Background Alzheimer's Disease Therapy In Patients With Moderate Severity Alzheimer's Disease
Status: Enrolling
Updated:  11/17/2016
Clinical Research Facility
mi
from
Jenkintown, PA
MAyflOwer RoAD Study: A Study of RO4602522 in Patients With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy
A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study To Investigate The Efficacy And Safety Of RO4602522 Added To Background Alzheimer's Disease Therapy In Patients With Moderate Severity Alzheimer's Disease
Status: Enrolling
Updated: 11/17/2016
Clinical Research Facility
mi
from
Jenkintown, PA
Click here to add this to my saved trials
MAyflOwer RoAD Study: A Study of RO4602522 in Patients With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy
A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study To Investigate The Efficacy And Safety Of RO4602522 Added To Background Alzheimer's Disease Therapy In Patients With Moderate Severity Alzheimer's Disease
Status: Enrolling
Updated:  11/17/2016
Clinical Research Facility
mi
from
Wyomissing, PA
MAyflOwer RoAD Study: A Study of RO4602522 in Patients With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy
A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study To Investigate The Efficacy And Safety Of RO4602522 Added To Background Alzheimer's Disease Therapy In Patients With Moderate Severity Alzheimer's Disease
Status: Enrolling
Updated: 11/17/2016
Clinical Research Facility
mi
from
Wyomissing, PA
Click here to add this to my saved trials
MAyflOwer RoAD Study: A Study of RO4602522 in Patients With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy
A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study To Investigate The Efficacy And Safety Of RO4602522 Added To Background Alzheimer's Disease Therapy In Patients With Moderate Severity Alzheimer's Disease
Status: Enrolling
Updated:  11/17/2016
Clinical Research Facility
mi
from
East Providence, RI
MAyflOwer RoAD Study: A Study of RO4602522 in Patients With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy
A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study To Investigate The Efficacy And Safety Of RO4602522 Added To Background Alzheimer's Disease Therapy In Patients With Moderate Severity Alzheimer's Disease
Status: Enrolling
Updated: 11/17/2016
Clinical Research Facility
mi
from
East Providence, RI
Click here to add this to my saved trials
MAyflOwer RoAD Study: A Study of RO4602522 in Patients With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy
A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study To Investigate The Efficacy And Safety Of RO4602522 Added To Background Alzheimer's Disease Therapy In Patients With Moderate Severity Alzheimer's Disease
Status: Enrolling
Updated:  11/17/2016
Clinical Research Facility
mi
from
Providence, RI
MAyflOwer RoAD Study: A Study of RO4602522 in Patients With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy
A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study To Investigate The Efficacy And Safety Of RO4602522 Added To Background Alzheimer's Disease Therapy In Patients With Moderate Severity Alzheimer's Disease
Status: Enrolling
Updated: 11/17/2016
Clinical Research Facility
mi
from
Providence, RI
Click here to add this to my saved trials
MAyflOwer RoAD Study: A Study of RO4602522 in Patients With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy
A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study To Investigate The Efficacy And Safety Of RO4602522 Added To Background Alzheimer's Disease Therapy In Patients With Moderate Severity Alzheimer's Disease
Status: Enrolling
Updated:  11/17/2016
Clinical Research Facility
mi
from
Charleston, SC
MAyflOwer RoAD Study: A Study of RO4602522 in Patients With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy
A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study To Investigate The Efficacy And Safety Of RO4602522 Added To Background Alzheimer's Disease Therapy In Patients With Moderate Severity Alzheimer's Disease
Status: Enrolling
Updated: 11/17/2016
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
MAyflOwer RoAD Study: A Study of RO4602522 in Patients With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy
A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study To Investigate The Efficacy And Safety Of RO4602522 Added To Background Alzheimer's Disease Therapy In Patients With Moderate Severity Alzheimer's Disease
Status: Enrolling
Updated:  11/17/2016
Clinical Research Facility
mi
from
Fort Worth, TX
MAyflOwer RoAD Study: A Study of RO4602522 in Patients With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy
A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study To Investigate The Efficacy And Safety Of RO4602522 Added To Background Alzheimer's Disease Therapy In Patients With Moderate Severity Alzheimer's Disease
Status: Enrolling
Updated: 11/17/2016
Clinical Research Facility
mi
from
Fort Worth, TX
Click here to add this to my saved trials
MAyflOwer RoAD Study: A Study of RO4602522 in Patients With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy
A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study To Investigate The Efficacy And Safety Of RO4602522 Added To Background Alzheimer's Disease Therapy In Patients With Moderate Severity Alzheimer's Disease
Status: Enrolling
Updated:  11/17/2016
mi
from
Darlinghurst,
MAyflOwer RoAD Study: A Study of RO4602522 in Patients With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy
A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study To Investigate The Efficacy And Safety Of RO4602522 Added To Background Alzheimer's Disease Therapy In Patients With Moderate Severity Alzheimer's Disease
Status: Enrolling
Updated: 11/17/2016
mi
from
Darlinghurst,
Click here to add this to my saved trials
Efficacy and Safety of MNI-672 SPECT for Detection/Exclusion of Cerebral B-amyloid in AD Subjects Compared to HVs.
An Exploratory, Open-label, Non-randomized Phase 1 Study to Evaluate the Efficacy and Safety of MNI-672 SPECT for Detection/Exclusion of Cerebral B-amyloid in Patients With Alzheimer's Disease Compared to Healthy Volunteers.
Status: Enrolling
Updated:  12/15/2016
Molecular Neuroimaging, LLC
mi
from
New Haven, CT
Efficacy and Safety of MNI-672 SPECT for Detection/Exclusion of Cerebral B-amyloid in AD Subjects Compared to HVs.
An Exploratory, Open-label, Non-randomized Phase 1 Study to Evaluate the Efficacy and Safety of MNI-672 SPECT for Detection/Exclusion of Cerebral B-amyloid in Patients With Alzheimer's Disease Compared to Healthy Volunteers.
Status: Enrolling
Updated: 12/15/2016
Molecular Neuroimaging, LLC
mi
from
New Haven, CT
Click here to add this to my saved trials
Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects
Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Clinically Diagnosed Tauopathies in Comparison to Healthy Subjects
Status: Enrolling
Updated:  12/15/2016
Molecular Neuroimaging, LLC
mi
from
New Haven, CT
Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects
Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Clinically Diagnosed Tauopathies in Comparison to Healthy Subjects
Status: Enrolling
Updated: 12/15/2016
Molecular Neuroimaging, LLC
mi
from
New Haven, CT
Click here to add this to my saved trials
Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies
Phase 0 Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Alzheimer's Disease and Other Tauopathies
Status: Enrolling
Updated:  12/15/2016
Molecular Neuroimaging, LLC
mi
from
New Haven, CT
Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies
Phase 0 Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Alzheimer's Disease and Other Tauopathies
Status: Enrolling
Updated: 12/15/2016
Molecular Neuroimaging, LLC
mi
from
New Haven, CT
Click here to add this to my saved trials
Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02)
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease
Status: Enrolling
Updated:  12/29/2016
Clinical Research Facility
mi
from
Baltimore, MD
Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02)
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease
Status: Enrolling
Updated: 12/29/2016
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02)
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease
Status: Enrolling
Updated:  12/29/2016
Clinical Research Facility
mi
from
Glendale, CA
Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02)
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease
Status: Enrolling
Updated: 12/29/2016
Clinical Research Facility
mi
from
Glendale, CA
Click here to add this to my saved trials
aeRobic Exercise and Cognitive Health
Aerobic Exercise for Alzheimer's Disease Prevention in At-Risk Middle-Aged Adults
Status: Enrolling
Updated:  12/29/2016
University of Wisconsin School of Medicine and Public Health
mi
from
Madison, WI
aeRobic Exercise and Cognitive Health
Aerobic Exercise for Alzheimer's Disease Prevention in At-Risk Middle-Aged Adults
Status: Enrolling
Updated: 12/29/2016
University of Wisconsin School of Medicine and Public Health
mi
from
Madison, WI
Click here to add this to my saved trials
A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions
Evaluation of [18F]PEB and Positron Emission Tomography (PET) as a Marker of mGluR5 in Subjects w/ Neuropsychiatric Conditions
Status: Enrolling
Updated:  1/5/2017
The Institute for Neurodegenerative Disorders
mi
from
New Haven, CT
A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions
Evaluation of [18F]PEB and Positron Emission Tomography (PET) as a Marker of mGluR5 in Subjects w/ Neuropsychiatric Conditions
Status: Enrolling
Updated: 1/5/2017
The Institute for Neurodegenerative Disorders
mi
from
New Haven, CT
Click here to add this to my saved trials
A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)
Single-Dose and Multiple-Dose, Dose-Escalation Study With LY2599666 to Evaluate the Safety, Pharmacokinetics, and Tolerability in Healthy Subjects and Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild-to-Moderate Alzheimer's Disease
Status: Enrolling
Updated:  1/5/2017
Parexel Early Phase Unit at Glendale
mi
from
Glendale, CA
A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)
Single-Dose and Multiple-Dose, Dose-Escalation Study With LY2599666 to Evaluate the Safety, Pharmacokinetics, and Tolerability in Healthy Subjects and Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild-to-Moderate Alzheimer's Disease
Status: Enrolling
Updated: 1/5/2017
Parexel Early Phase Unit at Glendale
mi
from
Glendale, CA
Click here to add this to my saved trials
A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)
Single-Dose and Multiple-Dose, Dose-Escalation Study With LY2599666 to Evaluate the Safety, Pharmacokinetics, and Tolerability in Healthy Subjects and Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild-to-Moderate Alzheimer's Disease
Status: Enrolling
Updated:  1/5/2017
CRI Lifetree
mi
from
Marlton, NJ
A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)
Single-Dose and Multiple-Dose, Dose-Escalation Study With LY2599666 to Evaluate the Safety, Pharmacokinetics, and Tolerability in Healthy Subjects and Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild-to-Moderate Alzheimer's Disease
Status: Enrolling
Updated: 1/5/2017
CRI Lifetree
mi
from
Marlton, NJ
Click here to add this to my saved trials
A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)
Single-Dose and Multiple-Dose, Dose-Escalation Study With LY2599666 to Evaluate the Safety, Pharmacokinetics, and Tolerability in Healthy Subjects and Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild-to-Moderate Alzheimer's Disease
Status: Enrolling
Updated:  1/5/2017
PRA Health Sciences
mi
from
Salt Lake City, UT
A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)
Single-Dose and Multiple-Dose, Dose-Escalation Study With LY2599666 to Evaluate the Safety, Pharmacokinetics, and Tolerability in Healthy Subjects and Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild-to-Moderate Alzheimer's Disease
Status: Enrolling
Updated: 1/5/2017
PRA Health Sciences
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)
Single-Dose and Multiple-Dose, Dose-Escalation Study With LY2599666 to Evaluate the Safety, Pharmacokinetics, and Tolerability in Healthy Subjects and Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild-to-Moderate Alzheimer's Disease
Status: Enrolling
Updated:  1/5/2017
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
mi
from
Kobe,
A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)
Single-Dose and Multiple-Dose, Dose-Escalation Study With LY2599666 to Evaluate the Safety, Pharmacokinetics, and Tolerability in Healthy Subjects and Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild-to-Moderate Alzheimer's Disease
Status: Enrolling
Updated: 1/5/2017
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
mi
from
Kobe,
Click here to add this to my saved trials
Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in Healthy Participants
A Randomized, Open-Label, Parallel-Arm Study to Assess the Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab (BIIB037) in Healthy Subjects Compared to a Single, Weight-Based Intravenous Dose
Status: Enrolling
Updated:  1/12/2017
Clinical Research Facility
mi
from
Evansville, IN
Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in Healthy Participants
A Randomized, Open-Label, Parallel-Arm Study to Assess the Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab (BIIB037) in Healthy Subjects Compared to a Single, Weight-Based Intravenous Dose
Status: Enrolling
Updated: 1/12/2017
Clinical Research Facility
mi
from
Evansville, IN
Click here to add this to my saved trials
Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in Healthy Participants
A Randomized, Open-Label, Parallel-Arm Study to Assess the Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab (BIIB037) in Healthy Subjects Compared to a Single, Weight-Based Intravenous Dose
Status: Enrolling
Updated:  1/12/2017
Clinical Research Facility
mi
from
Dallas, TX
Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in Healthy Participants
A Randomized, Open-Label, Parallel-Arm Study to Assess the Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab (BIIB037) in Healthy Subjects Compared to a Single, Weight-Based Intravenous Dose
Status: Enrolling
Updated: 1/12/2017
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
BPN14770 Single Ascending Dose Study in Healthy Male and Female Subjects
A Single Ascending Dose Study to Examine the Safety, Tolerability, and Pharmacokinetic Profile of BPN14770 in Healthy Male and Female Subjects
Status: Enrolling
Updated:  1/17/2017
Jasper Clinic, Inc.
mi
from
Kalamazoo, MI
BPN14770 Single Ascending Dose Study in Healthy Male and Female Subjects
A Single Ascending Dose Study to Examine the Safety, Tolerability, and Pharmacokinetic Profile of BPN14770 in Healthy Male and Female Subjects
Status: Enrolling
Updated: 1/17/2017
Jasper Clinic, Inc.
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
A Multiple Ascending Dose Study of BPN14770 in Healthy Young and Elderly Male or Female Subjects
A Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Examine the Safety, Tolerability, Pharmacokinetic, and Preliminary Cognitive Profile of BPN14770 in Healthy Young and Elderly Male and Female Subjects
Status: Enrolling
Updated:  1/17/2017
Jasper Clinic, Inc.
mi
from
Kalamazoo, MI
A Multiple Ascending Dose Study of BPN14770 in Healthy Young and Elderly Male or Female Subjects
A Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Examine the Safety, Tolerability, Pharmacokinetic, and Preliminary Cognitive Profile of BPN14770 in Healthy Young and Elderly Male and Female Subjects
Status: Enrolling
Updated: 1/17/2017
Jasper Clinic, Inc.
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Imaging Characteristics of a Follow-up 18F-AV-1451 Scan
An Open Label, Multicenter Study, Evaluating the Imaging Characteristics of a Follow-up 18F-AV-1451 Scan in Subjects Who Have Had a Prior 18F-AV-1451 Scan
Status: Enrolling
Updated:  2/8/2017
Hoag Memorial Hospital
mi
from
Newport Beach, CA
Imaging Characteristics of a Follow-up 18F-AV-1451 Scan
An Open Label, Multicenter Study, Evaluating the Imaging Characteristics of a Follow-up 18F-AV-1451 Scan in Subjects Who Have Had a Prior 18F-AV-1451 Scan
Status: Enrolling
Updated: 2/8/2017
Hoag Memorial Hospital
mi
from
Newport Beach, CA
Click here to add this to my saved trials
Imaging Characteristics of a Follow-up 18F-AV-1451 Scan
An Open Label, Multicenter Study, Evaluating the Imaging Characteristics of a Follow-up 18F-AV-1451 Scan in Subjects Who Have Had a Prior 18F-AV-1451 Scan
Status: Enrolling
Updated:  2/8/2017
Uc Irvine Medical Center
mi
from
Orange, CA
Imaging Characteristics of a Follow-up 18F-AV-1451 Scan
An Open Label, Multicenter Study, Evaluating the Imaging Characteristics of a Follow-up 18F-AV-1451 Scan in Subjects Who Have Had a Prior 18F-AV-1451 Scan
Status: Enrolling
Updated: 2/8/2017
Uc Irvine Medical Center
mi
from
Orange, CA
Click here to add this to my saved trials
Imaging Characteristics of a Follow-up 18F-AV-1451 Scan
An Open Label, Multicenter Study, Evaluating the Imaging Characteristics of a Follow-up 18F-AV-1451 Scan in Subjects Who Have Had a Prior 18F-AV-1451 Scan
Status: Enrolling
Updated:  2/8/2017
Massachusetts General Hospital
mi
from
Boston, MA
Imaging Characteristics of a Follow-up 18F-AV-1451 Scan
An Open Label, Multicenter Study, Evaluating the Imaging Characteristics of a Follow-up 18F-AV-1451 Scan in Subjects Who Have Had a Prior 18F-AV-1451 Scan
Status: Enrolling
Updated: 2/8/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Imaging Characteristics of a Follow-up 18F-AV-1451 Scan
An Open Label, Multicenter Study, Evaluating the Imaging Characteristics of a Follow-up 18F-AV-1451 Scan in Subjects Who Have Had a Prior 18F-AV-1451 Scan
Status: Enrolling
Updated:  2/8/2017
Center for Clinical Imaging Research at Washington University School of Medicine
mi
from
St. Louis, MO
Imaging Characteristics of a Follow-up 18F-AV-1451 Scan
An Open Label, Multicenter Study, Evaluating the Imaging Characteristics of a Follow-up 18F-AV-1451 Scan in Subjects Who Have Had a Prior 18F-AV-1451 Scan
Status: Enrolling
Updated: 2/8/2017
Center for Clinical Imaging Research at Washington University School of Medicine
mi
from
St. Louis, MO
Click here to add this to my saved trials
Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease
Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease
Status: Enrolling
Updated:  3/7/2017
Molecular Neuroimaging, LLC
mi
from
New Haven, CT
Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease
Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease
Status: Enrolling
Updated: 3/7/2017
Molecular Neuroimaging, LLC
mi
from
New Haven, CT
Click here to add this to my saved trials
Studying the Effects of Antihypertensives on Individuals at Risk for Alzheimer's
Studying the Effects of Antihypertensives on Individuals at Risk for Alzheimer's
Status: Enrolling
Updated:  3/28/2017
Wisconisn Alzheimer's Disease Research Center
mi
from
Madison, WI
Studying the Effects of Antihypertensives on Individuals at Risk for Alzheimer's
Studying the Effects of Antihypertensives on Individuals at Risk for Alzheimer's
Status: Enrolling
Updated: 3/28/2017
Wisconisn Alzheimer's Disease Research Center
mi
from
Madison, WI
Click here to add this to my saved trials
Tau Imaging in Professional Fighters
18F-AV-1451 PET Imaging in Professional Fighters
Status: Enrolling
Updated:  4/13/2017
Cleveland Clinic Lou Ruvo Center for Brain Health
mi
from
Las Vegas, NV
Tau Imaging in Professional Fighters
18F-AV-1451 PET Imaging in Professional Fighters
Status: Enrolling
Updated: 4/13/2017
Cleveland Clinic Lou Ruvo Center for Brain Health
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Effect of Insulin Sensitizer Metformin on AD Biomarkers
A Phase II Trial to Study the Effect of Metformin on AD Biomarkers: A Randomized Placebo Controlled Crossover Pilot Study of Metformin Effects on Cognitive, Physiological and Biochemical Biomarkers of MCI and Dementia Due to AD
Status: Enrolling
Updated:  4/25/2017
University of Pennsylvania, Penn Memory Center
mi
from
Philadelphia, PA
Effect of Insulin Sensitizer Metformin on AD Biomarkers
A Phase II Trial to Study the Effect of Metformin on AD Biomarkers: A Randomized Placebo Controlled Crossover Pilot Study of Metformin Effects on Cognitive, Physiological and Biochemical Biomarkers of MCI and Dementia Due to AD
Status: Enrolling
Updated: 4/25/2017
University of Pennsylvania, Penn Memory Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Down Syndrome Biomarker Initiative (DSBI)
Down Syndrome Biomarker Initiative: A Natural History Study of Alzheimer's Disease in Down Syndrome (Pilot Study)
Status: Enrolling
Updated:  5/1/2017
The University of California, San Diego
mi
from
La Jolla, CA
Down Syndrome Biomarker Initiative (DSBI)
Down Syndrome Biomarker Initiative: A Natural History Study of Alzheimer's Disease in Down Syndrome (Pilot Study)
Status: Enrolling
Updated: 5/1/2017
The University of California, San Diego
mi
from
La Jolla, CA
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
University of Alabama at Birmingham, Department of Neurology, Memory Disorders Division
mi
from
Birmingham, AL
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
University of Alabama at Birmingham, Department of Neurology, Memory Disorders Division
mi
from
Birmingham, AL
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
Banner Alzheimer'S Institute
mi
from
Phoenix, AZ
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
Banner Alzheimer'S Institute
mi
from
Phoenix, AZ
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
HOPE Research Institute
mi
from
Phoenix, AZ
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
HOPE Research Institute
mi
from
Phoenix, AZ
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
Principals Research Group
mi
from
Hot Springs, AR
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
Principals Research Group
mi
from
Hot Springs, AR
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
Clinical Trials, Inc.
mi
from
Little Rock, AR
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
Clinical Trials, Inc.
mi
from
Little Rock, AR
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
CITrials, Inc.
mi
from
Bellflower, CA
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
CITrials, Inc.
mi
from
Bellflower, CA
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
Southern Research LLC
mi
from
Beverly Hills, CA
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
Southern Research LLC
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
ATP Clinical Research, Inc.
mi
from
Costa Mesa, CA
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
ATP Clinical Research, Inc.
mi
from
Costa Mesa, CA
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
Diligent Clinical Trials
mi
from
Downey, CA
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
Diligent Clinical Trials
mi
from
Downey, CA
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
UCSD Comprehensive Alzheimer's Program
mi
from
La Jolla, CA
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
UCSD Comprehensive Alzheimer's Program
mi
from
La Jolla, CA
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
Alliance Research Centers
mi
from
Laguna Hills, CA
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
Alliance Research Centers
mi
from
Laguna Hills, CA
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
Senior Clinical Trials, Inc.
mi
from
Laguna Hills, CA
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
Senior Clinical Trials, Inc.
mi
from
Laguna Hills, CA
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
Collaborative Neuroscience Network, Inc.
mi
from
Long Beach, CA
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
Collaborative Neuroscience Network, Inc.
mi
from
Long Beach, CA
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
Alliance Research
mi
from
Long Beach, CA
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
Alliance Research
mi
from
Long Beach, CA
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
Renew Behavioral Health
mi
from
Long Beach, CA
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
Renew Behavioral Health
mi
from
Long Beach, CA
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
Pacific Research Network
mi
from
San Diego, CA
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
Pacific Research Network
mi
from
San Diego, CA
Click here to add this to my saved trials
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated:  5/16/2017
Artemis Institute for Clinical Research
mi
from
San Diego, CA
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Status: Enrolling
Updated: 5/16/2017
Artemis Institute for Clinical Research
mi
from
San Diego, CA
Click here to add this to my saved trials